Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Dr. Richard Furman of Weill Cornell in Manhattan is a leading researcher in CLL and one of the earliest proponents of a non-chemo approach to managing chronic lymphocytic leukemia. Always on
At the 2017 ASH Annual Meeting, Dr. Brian Koffman interviewed Dr. Jennifer Brown from Dana Farber Cancer Institute at Harvard University in Boston regarding the association between idelalisib and liver inflammation
At the 2017 ASH Annual Meeting in Atlanta, GA, Dr. Brian Koffman interviewed Dr. George Follows from the Cambridge University Hospital in the UK regarding clinical data regarding the combination of venetoclax and rituximab.
By Larry Marion – Patient A few days before Thanksgiving in 2005 I was diagnosed with chronic lymphocytic leukemia, discovered by accident during my annual physical — I had no symptoms.
MARCH 26, 2018 I am four days past my CAR-T infusion and a week past my chemo to reduce my lymphocytes to allow the CAR-Ts to be gracefully accepted into my
The abnormal white blood cells or “leukemic cells” produced in chronic lymphocytic leukemia (CLL) can reside for years in various parts of the body, slowly and discretely accumulating in bone marrow,
By Manali Kamdar, MD The presentation and course of CLL is strikingly varied in patients, with some individuals presenting with a biologically indolent course whereas others present with an aggressive course.
There is little question that the approval of kinase inhibitor therapies such as ibrutinib have revolutionized the care of patients with CLL. Ibrutinib is active in many circumstances where many traditional
The beginning of Blood Cancer Awareness Month (#BCAM) started with a bang with the August 30, 2017 approval of the first gene therapy in the USA. Quoting from the FDA press
One click to our most popular content.
